Cytotoxic Effect of 6-Ethyl-Chenodeoxycholic Acid and Cabazitaxel on PC-3 Cells

Introduction. Chemotherapy with Cabazitaxel (CBZ) is a typical first-line treatment option for naïive castration-resistant prostate cancer resistant to docetaxel. On the other hand, Cabazitaxel's therapeutic success constrained by chemoresistance and side effects. Aim. To assess whether 6 alpha-ethylchenodeoxycholic acid (6-ECDCA), selective agonist bile receptors will enhance efficacy of CBZ in androgen-independent cells. Materials methods. The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay was used cytotoxicity 6-ECDCA medicines or their combinations against human cell line (PC-3). combination outcome suggested Chou TC et al. then evaluated using index (CI) find out nature synergism, antagonism, additive effect drug’s combination. Furthermore, Dose-Reduction Index (DRI) determined measure how many times dose could be reduced each drug synergistic Results discussion. Analysis dose-effect curve showed that PC-3 cells alone combined 48 h led 50 % 20.5 nM 4.7 nM, respectively. at 1.77 µM had an based on CI value, which 1.02, while 21.02 µM, 0.54 designates strong effect. submaximal lower 6-folds one produced 95 death than either agent alone. Conclusion. Combination plot ≤ l all this study, indicates interactions between 6-ECDCA. significant impact treating confirmed study preferred single drug.